Skip to main content

Table 5 List of SHPT medication changes before and after the study

From: Effect of switching from cinacalcet to etelcalcetide on secondary hyperparathyroidism in patients undergoing hemodialysis: an ESCORT trial

  

Dose of cinacalcet hydrochloride before switching

SHPT-related agent

Time

25 mg

50 mg

≥ 75 mg

Total

Active vitamin D agent

SCR

48 (90.6)

18 (100.0)

17 (89.5)

83 (92.2)

24 weeks

50 (94.3)

17 (94.4)

18 (94.7)

85 (94.4)

Ca-based phosphate binder

SCR

30 (56.6)

9 (50.0)

7 (36.8)

46 (51.1)

24 weeks

33 (62.3)

9 (50.0)

6 (31.6)

48 (53.3)

Lanthanum carbonate

SCR

37 (69.8)

14 (77.8)

15 (78.9)

66 (73.3)

24 Weeks

34 (64.2)

14 (77.8)

13 (68.4)

61 (67.8)

Sevelamer

SCR

14 (26.4)

8 (44.4)

7 (36.8)

29 (32.2)

24 weeks

12 (22.6)

7 (38.9)

7 (36.8)

26 (28.9)

Iron-based phosphate binder

SCR

14 (26.4)

2 (11.1)

7 (36.8)

23 (25.6)

24 weeks

12 (22.6)

2 (11.1)

6 (31.6)

20 (22.2)

Bixalomer

SCR

6 (11.3)

1 ( 5.6)

1 ( 5.3)

8 ( 8.9)

24 weeks

5 ( 9.4)

1 ( 5.6)

1 ( 5.3)

7 ( 7.8)

  1. SHPT secondary hyperparathyroidism, SCR screening